Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting? Journal Article
| Authors: | Casulo, C.; Horwitz, S. |
| Article Title: | Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting? |
| Abstract: | Peripheral T-cell lymphomas (PTCL) are rare and aggressive subtypes of non-Hodgkin's lymphoma. Compared to B cell lymphomas, the immunologic phenotype of PTCL portends a poorer prognosis, with the exception of anaplastic large cell lymphoma bearing the anaplastic lymphoma kinase protein. Patients with PTCL tend to present clinically in advanced disease states, show lower response rates to chemotherapy, and suffer from more frequent relapses and shorter remissions. The rarity of these lymphomas has made it difficult to carry out prospective, randomized trials delineating optimal treatments. Conventional and intensified chemotherapy have led to reasonable responses, but in many studies, frequent relapses. Consequently, high-dose chemotherapy and autologous stem cell transplantation (ASCT) have been actively studied in both the relapsed and upfront setting. In addition, the impact of disease status at transplantation is being investigated, though the optimal disease state at transplant is still a matter of debate, as is the timing of transplant. This article seeks to review the literature on the role of ASCT in PTCL, as well as to clarify what may be the optimal disease state in which to offer patients with PTCL autologous transplantation, if at all. © 2010 Springer Science+Business Media, LLC. |
| Keywords: | cancer survival; event free survival; treatment outcome; treatment response; disease-free survival; survival rate; overall survival; prednisone; allogeneic stem cell transplantation; clinical trial; review; salvage therapy; cisplatin; doxorubicin; cancer combination chemotherapy; cancer growth; gemcitabine; cancer radiotherapy; disease free survival; combined modality therapy; cytarabine; methotrexate; drug megadose; antineoplastic agent; prospective study; progression free survival; multiple cycle treatment; etoposide; antineoplastic combined chemotherapy protocols; risk factors; randomized controlled trials as topic; recurrence; cyclophosphamide; dexamethasone; vincristine; autologous stem cell transplantation; hematopoietic stem cell transplantation; retrospective study; ifosfamide; survival time; lymphoma, b-cell; cancer regression; cutaneous t cell lymphoma; peripheral t cell lymphoma; non-hodgkin's lymphoma; disease progression; mitoxantrone; transplantation conditioning; asparaginase; bleomycin; cancer relapse; vindesine; methylprednisolone; anthracycline derivative; transplantation, autologous; aggressive lymphoma; complete remission; high-dose therapy; peripheral t-cell lymphoma; upfront setting; lymphoma, t-cell, peripheral |
| Journal Title: | Current Oncology Reports |
| Volume: | 12 |
| Issue: | 6 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2010-11-01 |
| Start Page: | 374 |
| End Page: | 382 |
| Language: | English |
| DOI: | 10.1007/s11912-010-0125-0 |
| PUBMED: | 20737300 |
| PROVIDER: | scopus |
| PMCID: | PMC4075438 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 20 April 2011" - "CODEN: CORUA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work